Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Controversial social media posts by socialist Congressional contender for Manhattan, Darializa Avila Chevalier, that criticized U.S. service members have resurfaced. Avila Chevalier, a member of the ...

The Democratic Party’s socialist wing is taking a victory lap after more than a dozen Democratic Socialists of America, or DSA, backed candidates won or are expected to advance in primaries across ...

Los Angeles’ progressive movement is showing fresh cracks, with a split happening in the middle of the city’s high-stakes mayoral race. The endorsements from Hernandez and Jurado join fellow ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...

Americans pay too little attention to local politics. A decade ago, progressive billionaire George Soros took advantage of this fact, pouring millions into local races to get progressive district ...

The 2026 Los Angeles municipal election cycle has emerged as a devastating exposure of the political character of the Democratic Socialists of America (DSA) and its local affiliate, DSA-LA. There are ...

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

The consensus mark for RXRX's Q4 loss and sales are pinned at 28 cents per share and $25.5M, respectively. In late 2025, RXRX highlighted REC-4881 data showing rapid, durable polyp reductions in FAP ...